ArriVent CEO granted 550,000 stock options

ArriVent BioPharma’s President and CEO, Zhengbin Yao, reported a new stock option grant.

Rhea-AI Filing Summary

ArriVent BioPharma’s President and CEO, Zhengbin Yao, reported a new stock option grant. On February 2, 2026, he received an option to purchase 550,000 shares of common stock at an exercise price of $22.67 per share.

According to the filing, 25% of the option vests on February 2, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, contingent on his continued service. Following this grant, he beneficially owns 550,000 derivative securities directly.

Insights

Equity Compensation Analyst

Large CEO option grant with multi‑year, service-based vesting.

The filing shows Zhengbin Yao, President and CEO of ArriVent BioPharma, receiving a stock option for 550,000 shares at an exercise price of $22.67 on February 2, 2026. The option is held directly and represents a significant equity incentive.

The vesting schedule is structured to promote retention: 25% vests on February 2, 2027, and the remainder vests in 36 equal monthly installments thereafter, conditioned on continued service. This ties most of the potential upside to a multi‑year commitment by the CEO.

Because this is a compensatory award rather than an immediate share sale or purchase, and no broader financial metrics are disclosed here, its standalone effect on an investment thesis is limited. Future company filings may provide more context on overall equity compensation levels and dilution.

Insider Trade Summary

Grant/Award: 550,000 shares

Grant/Award 1 txn

Insider Yao Zhengbin

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	550,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 550,000 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this option vest as to 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ArriVent BioPharma (AVBP) report in this Form 4 filing?

ArriVent BioPharma reported that President and CEO Zhengbin Yao received a new stock option grant. The option covers 550,000 shares of common stock at an exercise price of $22.67 per share, recorded as a directly held derivative security.

How many ArriVent BioPharma (AVBP) stock options were granted to the CEO?

The CEO, Zhengbin Yao, was granted a stock option for 550,000 shares of ArriVent BioPharma common stock. This entire amount is shown as beneficially owned following the reported transaction and is classified as directly held derivative securities in the filing.

What is the exercise price of Zhengbin Yao’s ArriVent BioPharma stock option?

The exercise price of the CEO’s stock option is $22.67 per share. This means he can buy up to 550,000 shares of ArriVent BioPharma common stock at $22.67, subject to the vesting schedule and his continued service with the company.

When do Zhengbin Yao’s new ArriVent BioPharma options start vesting?

Vesting begins on February 2, 2027, when 25% of the option vests. The remaining 75% then vests in 36 equal monthly installments, provided Zhengbin Yao continues to serve the company through each applicable vesting date as described in the filing.

How are the ArriVent BioPharma CEO’s new options structured for vesting?

The option vests in two phases: 25% vests on February 2, 2027, and the remaining portion vests over 36 monthly installments. This schedule is contingent on the CEO’s continued service, aligning the grant with long-term retention and performance incentives.

Does Zhengbin Yao hold the ArriVent BioPharma stock options directly or indirectly?

The filing classifies the 550,000 stock options as held directly by Zhengbin Yao. The ownership form is marked as “D” for direct, and no footnotes indicate that the options are held through a separate entity, trust, or other indirect structure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 08:40 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yao Zhengbin

(Last) (First) (Middle)

C/O ARRIVENT BIOPHARMA, INC.

18 CAMPUS BOULEVARD, SUITE 100

(Street)

NEWTOWN SQUARE PA 19073

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ArriVent BioPharma, Inc. [ AVBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$22.67	02/02/2026		A		550,000		(1)	02/02/2036	Common Stock	550,000	$0	550,000	D

Explanation of Responses:

1. The shares underlying this option vest as to 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ James Kastenmayer, Attorney-in-Fact for Zhengbin Yao	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.